BioNTech SE (BNTX)
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
BioNTech says FDA lifts partial hold on its cancer drug trial
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Markets Yifeng Liu - HSBC Bank Plc Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Chris Shibutani - Goldman Sachs Simon Baker - Redburn Atlantic Eliana Merle - UBS John Newman - Canaccord Genuity Manos Mastorakis - Deutsche Bank Operator Welcome to BioNTech's Second Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement with biotech firm Genmab to develop a lung cancer drug.
BioNTech's stock slides 4% after earnings fall short of estimates as COVID vaccine falls slide
BioNTech SE's stock BNTX, +1.65% fell 4% early Monday, after the company's second-quarter earnings fell short of estimates amid a continued slide in sales of its COVID-19 vaccine. The company had a net loss of 807.8 million euros ($883.5 million), or $3.36 a share, for the quarter, wider than the los of EUR109.4 million, or 79 cents a share, posted in the year-earlier period.
BioNTech widens loss to 807.8 mln euro in second quarter
Losses at Germany's BioNTech quadrupled year-on-year in the second quarter, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sales of its COVID-19 vaccine.
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday.
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer drug.
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants
COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.
Why Vaccine Stocks Rallied This Week
H5N1 bird flu was detected this week in Michigan and Australia. It's the first detection in humans since March, when news of an outbreak in cattle emerged.
